Seven days post orthotopic tumor implantation, a single 100 μg dose of agonistic αCD40 (FGK45, BioXcell) was administered alone or in combination with 200 μg αPD-L1 (10F.9G2, BioXcell) on days 7, 10, and 12 i.p. [28 (link)]. 200 μg of αCxcr3 (CXCR-173, BioXcell) was administered on days 6, 9 and 12.